RecruitingPhase 3NCT07174427
Multi-center Study of TBI-1301 (INN: Mipetresgene Autoleucel; Mip-cel) in Patients With NY-ESO-1 Positive Synovial Sarcoma
Sponsor
Takara Bio Inc.
Enrollment
5 participants
Start Date
Jan 5, 2026
Study Type
INTERVENTIONAL
Conditions
Summary
The purpose of this study is to verify the safety and the efficacy of TBI-1301 for NY-ESO-1 expressing synovial sarcoma when administered following cyclophosphamide/fludarabine pre-treatment.
Eligibility
Min Age: 18 Years
Inclusion Criteria12
- ≥ 18 years of age
- Histologically confirmed synovial sarcoma
- Surgically unresectable tumor
- Progressing or recurrent synovial sarcoma which has been treated with 1-4 regimens of systemic chemotherapies including anthracycline
- HLA-A\*02:01 or HLA-A\*02:06 positive
- Tumor that express NY-ESO-1 by immunohistochemistry
- Measurable lesions that are evaluable by the RECIST ver1.1
- ECOG Performance Status of 0, 1 or 2
- No treatment such as chemotherapy and be expected to recover fully from the previous treatment at the time of the lymphocytes collection for manufacturing
- Life expectancy ≥ 16 weeks after consent
- No severe damage on the major organs (bone marrow, heart, lung, liver, kidney, etc) and meet the following lab value criteria; Total bilirubin ≤ 1.5 x upper limit of normal (ULN); AST(GOT), ALT(GPT) \< 3.0 x ULN; Creatinine \< 1.5 x ULN; 2,500/μL \< WBC ≤ULN; Hemoglobin ≥ 8.0g/dL; Platelets ≥ 75,000/μL
- Patients must be able to understand the study contents and to give a written consent at his/her free will.
Exclusion Criteria13
- Patients with the following conditions are excluded from the study; Unstable angina, cardiac infarction, or heart failure; Uncontrolled diabetes or hypertension; Active infection; Obvious interstitial pneumonia or lung fibrosis by chest X-ray; Active autoimmune disease requiring steroids or immunosuppressive therapy.
- Active metastatic tumor cell invasion into CNS
- Active multiple cancer
- Positive for HBs antigen or HBV-DNA observed in serum
- Positive for HCV antibody and HCV-RNA observed in serum
- Positive for antibodies against HIV or HTLV-1
- History of serious hypersensitivity reactions to bovine or murine derived substances.
- History of hypersensitivity reaction to ingredients or excipients of investigational drugs used in this study
- History of hypersensitivity reaction to antibiotics used in manufacturing for the investigational drug used in this study.
- History of treatment with cell therapy or gene therapy
- Alcohol or drug dependence that may interfere with study participation
- Pregnant females, lactating females (except when they cease and do not resume lactation) or female and male patients who cannot agree to practice the adequate birth control from the consent to 6 months after infusion of the investigational drug.
- Clinically significant systemic illness that in the judgment of the PI or sub-investigator would compromise the patient's ability to tolerate protocol therapy or significantly increase the risk of complications.
Interventions
BIOLOGICALTBI-1301
Split dose of TBI-1301 is administered intravenously for 2 days following cyclophosphamide/fludarabine pre-treatment.
DRUGCyclophosphamide
Cyclophosphamide (750mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
DRUGFludarabine
Fludarabine (30mg/m2/day x 2 days Intravenous (IV)) is administered as pre-treatment medication of TBI-1301.
Locations(2)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07174427
Related Trials
Hypofractionated, 3-week, Preoperative Proton or X-ray Radiotherapy for Patients With Localized Soft Tissue Sarcoma
NCT071693444 locations
Dose-escalated, Hypofractionated, Definitive Proton Radiotherapy for Patients With Inoperable Soft Tissue Sarcoma.
NCT071739722 locations
AOH1996 for the Treatment of Refractory Solid Tumors
NCT052273262 locations